C
Cabaletta Bio, Inc. (CABA)
NMS – Real vaqt narxi. Valyuta: USD
3.63
-0.19 (-4.97%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
3.63
-0.19 (-4.97%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Cabaletta Bio, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, autoimmün kasalliklarga chalingan bemorlar uchun genetik jihatdan o'zgartirilgan T-hujayra terapiyalarini kashf qilish va ishlab chiqishga e'tibor qaratadi. Kompaniyaning asosiy mahsuloti nomzodi resekabtagene autoleucel hisoblanadi, bu 4-1BB ko'stimulyatsion domenini o'z ichiga olgan to'liq inson CD19-CAR T-hujayrasi bo'lib, u dermatomiozit, antisintetaza sindromi, immunitet vositasidagi nekrotik miopatiya, yoshlik miyoziti, lupus nefriti, tizimli qizil yug'rich, takrorlanuvchi va progressiv ko'p skleroz, mukokutan va shilliq pardali pemfigus vulgaris (PV), tizimli skleroz va umumiy miyasteniya gravisni davolash uchun 1/2-bosqichli klinik sinovlarda. Shuningdek, u shilliq pardali PVni davolash uchun 1-bosqichli klinik sinovda bo'lgan CAAR T-hujayra terapiyasi DSG3-CAARTni; va mushak-maxsus kinaz (MuSK) antitelalari bilan bog'liq miyasteniya gravis bilan og'rigan bemorlarni davolash uchun 1-bosqichli sinovda bo'lgan tadqiqot hujayrasi terapiyasi MuSK-CAARTni ishlab chiqadi. Kompaniya Pensilvaniya universiteti va Filadelfiya bolalar kasalxonasi; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; va WuXi Advanced Therapies, Inc. bilan hamkorlik qiladi. Kompaniya ilgari Tycho Therapeutics, Inc. nomi bilan tanilgan va 2018-yil avgust oyida Cabaletta Bio, Inc. nomini o'zgartirgan. Cabaletta Bio, Inc. 2017-yilda ro'yxatga olingan va shtab-kvartirasi Filadelfiya, Pensilvaniya shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Aimee Payne M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board |
| Dr. David J. Chang FACR, M.D., M.P.H. | Chief Medical Officer |
| Dr. Gwendolyn K. Binder Ph.D. | President of Science & Technology |
| Dr. Michael C. Milone M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board |
| Dr. Qing Sarah Yuan Ph.D. | Chief Technology Officer |
| Dr. Samik Basu M.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-28 | DEFA14A | d923183ddefa14a.htm |
| 2026-04-28 | DEF 14A | d922609ddef14a.htm |
| 2026-04-20 | 8-K | caba-20260420.htm |
| 2026-04-17 | PRE 14A | d922609dpre14a.htm |
| 2026-03-23 | S-8 | caba-20260323.htm |
| 2026-01-12 | 8-K | caba-20260112.htm |
| 2025-11-10 | 8-K | caba-20251110.htm |
| 2025-10-29 | 8-K | caba-20251029.htm |
| 2025-10-27 | 8-K | caba-20251027.htm |
| 2025-10-09 | 8-K | caba-20251009.htm |
| Chief Scientific Officer |
| Dr. Steven A. Nichtberger M.D. | Co-Founder, Chairman, CEO & President |
| Mr. Anup Marda M.B.A. | Chief Financial Officer |
| Mr. Michael Gerard J.D. | General Counsel & Secretary |
| Ms. Heather Harte-Hall M.Sc. | Chief Compliance Officer |